Literature DB >> 24810446

Encephalopathy in an infant with infantile spasms: possible role of valproate toxicity.

Shobhana Sivathanu1, Sowmya Sampath, Madhubala Veerasamy, Satheeshkumar Sunderkumar.   

Abstract

An infant presented with global developmental delay and infantile spasms. EEG was suggestive of hypsarrhythmia. She was started on sodium valproate, clonazepam and adrenocorticotropic hormone injection. After an initial improvement the child developed vomiting, altered sensorium and increase in frequency of seizures suggestive of encephalopathy. Valproate-induced hyperammonaemia or hepatic encephalopathy was considered and the drug was withheld following which there was a dramatic improvement. Paradoxically, the liver function tests and serum ammonia were normal. However, a complete reversal of encephalopathy, on withdrawal of the drug, strongly suggested an adverse drug reaction (ADR) due to valproic acid. Marginal elevation of serum valproic acid prompted us to use the Naranjo ADR probability score to confirm the diagnosis. This case highlights the fact that valproate toxicity can manifest with normal liver function and serum ammonia levels. This is the youngest reported case with this rare form of valproate-induced encephalopathy.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24810446      PMCID: PMC3992611          DOI: 10.1136/bcr-2013-200895

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  10 in total

1.  Valproate-induced hyperammonemic encephalopathy in the presence of topiramate.

Authors:  H M Hamer; S Knake; U Schomburg; F Rosenow
Journal:  Neurology       Date:  2000-01-11       Impact factor: 9.910

2.  Two cases of valproate-induced hyperammonemic encephalopathy without hepatic failure.

Authors:  Samhita Panda; K Radhakrishnan
Journal:  J Assoc Physicians India       Date:  2004-09

3.  Serum and CSF glutamine levels in valproate-related hyperammonemic encephalopathy.

Authors:  David G Vossler; Alan J Wilensky; David F Cawthon; Diana L Abson Kraemer; Linda M Ojemann; Lisa M Caylor; John D Morgan
Journal:  Epilepsia       Date:  2002-02       Impact factor: 5.864

4.  Valproate-induced hyperammonemic encephalopathy with normal liver function.

Authors:  Amitav Rath; T Jaishree Naryanan; G V S Chowdhary; J M K Murthy
Journal:  Neurol India       Date:  2005-06       Impact factor: 2.117

5.  Valproate-induced encephalopathy.

Authors:  W T Chen; D J Yen; H Y Yu; K K Liao
Journal:  Zhonghua Yi Xue Za Zhi (Taipei)       Date:  2001-08

6.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

7.  Valproic acid induced encephalopathy--19 new cases in Germany from 1994 to 2003--a side effect associated to VPA-therapy not only in young children.

Authors:  Thorsten Gerstner; Deike Buesing; Elke Longin; Claudia Bendl; Dieter Wenzel; Brigitte Scheid; Gisela Goetze; Alfons Macke; Gerhard Lippert; Wolfgang Klostermann; Geert Mayer; Regine Augspach-Hofmann; Sabine Fitzek; Carl-Albrecht Haensch; Markus Reuland; Stephan A Koenig
Journal:  Seizure       Date:  2006-06-19       Impact factor: 3.184

8.  Topiramate enhances the risk of valproate-associated side effects in three children.

Authors:  Elke Longin; Martin Teich; W Koelfen; Stefan König
Journal:  Epilepsia       Date:  2002-04       Impact factor: 5.864

9.  Pharmacoepidemiologic investigation of a clonazepam-valproic acid interaction by mixed effect modeling using routine clinical pharmacokinetic data in Japanese patients.

Authors:  E Yukawa; T Nonaka; M Yukawa; S Higuchi; T Kuroda; Y Goto
Journal:  J Clin Pharm Ther       Date:  2003-12       Impact factor: 2.512

Review 10.  Science review: carnitine in the treatment of valproic acid-induced toxicity - what is the evidence?

Authors:  Philippe E R Lheureux; Andrea Penaloza; Soheil Zahir; Mireille Gris
Journal:  Crit Care       Date:  2005-06-10       Impact factor: 9.097

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.